Cannabics Pharmaceuticals Submits Protocol for an Ex-Vivo Clinical Study on Biopsies and Cannabinoids
Cannabics has submitted a protocol for the Helsinki Committee to conduct a nationwide study on fresh biopsies treated with a multitude of cannabinoid compounds and chemotherapies
TEL AVIV, Israel and BETHESDA, Maryland, Feb. 19, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has submitted a protocol for the Helsinki Committee to conduct a nationwide study which will apply Cannabics' high throughput screening platform to analyze the anti-tumor properties of cannabinoid compounds and chemotherapies on fresh biopsies. If the proposed study is approved, Cannabics will be able to obtain, upon patients' consent, a live biopsy and blood sample and perform drug sensitivity and drug resistance tests.
This protocol is part of Cannabics' ongoing mission to commercialize its personalized diagnostics and apply its technology to Cannabinoids and chemotherapy, which in turn will provide doctors and their patients' supportive data for more informed treatment decisions.
Dr. Eyal Ballan, CTO and Co-Founder of Cannabics, said, "This ex-vivo study is a continuum of our in-vitro study searching for apoptotic effects of Cannabinoids in a personalized manner. We believe it is the first time Cannabinoids are being tested on live biopsies. Our aim is to incorporate cannabis growers, locally and globally, and invest further in mapping their cannabinoid repertoire in order to provide individual tailored treatments for cancer patients."
About Cannabics
Pharmaceuticals
Cannabics Pharmaceuticals
Inc. (CNBX) is a U.S public company that is developing a platform
which leverages novel drug-screening tools and artificial
intelligence to create cannabinoid-based therapies for cancer that
are more precise to a patient's profile. By developing tools to
assess effectiveness on a personalized basis, Cannabics is helping
to move cannabinoids into the future of cancer therapy. The
company's R&D is based in Israel, where it is
licensed by the Ministry of Health to conduct scientific and
clinical research on cannabinoid formulations and Cancer. For
more information, please visit www.cannabics.com.
For the latest updates on Cannabics Pharmaceuticals follow the company on Twitter @cannabics1, Facebook @CannabicsPharmaceuticals, LinkedIn, and on Instagram @Cannabics_Pharmaceuticals.
Disclaimer:
Certain
statements contained in this release may constitute forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 and other U.S. Federal securities laws. Such
statements include but are not limited to statements identified by
words such as "believes," "expects," "anticipates," "estimates,"
"intends," "plans," "targets," "projects" and similar expressions.
For example, we are using forward-looking statements when we
discuss the protocol and the proposed clinical study, the
performance of drug sensitivity and drug resistance tests if
the clinical study is approved, our ongoing mission to
commercialize our personalized diagnostics and potentially provide
doctors and their patients supportive data for more informed
treatment decisions, the belief that the protocol further supports
efforts in establishing a library of cannabinoid compositions and
our aim to incorporate cannabis growers, locally and globally, and
invest further in mapping their cannabinoid repertoire in order to
provide individual tailored treatments for cancer patients. The
statements in this release are based upon the current beliefs and
expectations of our company's management and are subject to
significant risks and uncertainties. Actual results may differ from
those set forth in the forward-looking statements. Numerous factors
could cause or contribute to such differences, including, but not
limited to, results of clinical trials and/or other studies, the
challenges inherent in new product development initiatives, the
effect of any competitive products, our ability to license and
protect our intellectual property, our ability to raise additional
capital in the future that is necessary to maintain our business,
changes in government policy and/or regulation, potential
litigation by or against us, any governmental review of our
products or practices, as well as other risks discussed from time
to time in our filings with the Securities and Exchange Commission.
We undertake no duty to update any forward-looking statement or any
information contained in this press release or in other public
disclosures at any time. Finally, the investing public is reminded
that the only announcements or information about Cannabics
Pharmaceuticals Inc. which are condoned by the Company must emanate
from the Company itself and bear our name as its source.
For more information about
Cannabics:
Cannabics Pharmaceuticals
Inc.
Phone: +1 (877)
424-2429
[email protected]
http://www.cannabics.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/cannabics-pharmaceuticals-submits-protocol-for-an-ex-vivo-clinical-study-on-biopsies-and-cannabinoids-300797863.html